Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT062 in Relapsed/Refractory Multiple Myeloma
NCT01001442Phase 2Completed
- Sponsor
- Biotest AG
- Start
- Aug 2010
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of indatuximab ravtansine in multiple myeloma (MM), sponsored by Biotest AG. Started Aug 2010; status: completed.
02
Drugs
indatuximab ravtansine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01001442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001442.